-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tigilanol Tiglate in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tigilanol Tiglate in Soft Tissue Sarcoma Drug Details: Tigilanol tiglate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Laryngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Laryngeal CancerDrug Details:Tigilanol tiglate (EBC-46) is under development for the treatment of refractory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Salivary Gland Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Salivary Gland Cancer Drug Details:Tigilanol tiglate (EBC-46) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Paranasal Sinus And Nasal Cavity Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Paranasal Sinus And Nasal Cavity CancerDrug Details:Tigilanol tiglate (EBC-46) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Metastatic Colorectal CancerDrug Details:Tigilanol tiglate (EBC-46) is under development for the treatment of...
-
Company Profile
Eagle Bancorp Inc – Company Profile
Eagle Bancorp Inc (EBC) is a bank holding company that provides commercial and retail banking solutions through its subsidiary, Eagle Bank. It offers checking, escrow, and savings accounts; debit and credit cards; and certificate of deposits. The company provides loans for home, mortgage, personal and commercial purposes, vehicle purchase, and construction and real estate, and other personal and business requirements. It acts as an insurance agent and provides insurance coverage for life, property, business protection, casualty, long-term care, valuable articles,...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tigilanol tiglate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tigilanol tiglate Drug Details Tigilanol tiglate (EBC-46) is under development for the treatment of...
-
Product Insights
Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
A Burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers. The Burn - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Burn, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The...
-
Product Insights
Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed, discoloration and darkening of skin around the ulcer, hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle, and small, smooth areas of white...
-
Product Insights
Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers - Drugs in Development, 2021, provides an overview of the Venous Leg Ulcers (Dermatology) pipeline landscape. Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration...